Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Videos
Behind the Science, ep. 13: SPE vs. matr...
MinION: a portable analysis device for D...

Featured Products

Webcasts
Webcast - Driving Innovation in Antibody Discovery and Development Through Novel Partnership ModelsDriving Innovation in Antibody Discovery and Development Through Novel Partnership Models
In this webinar, Dr Robert Williams, Chief Development Scientist, Cancer Research UK, will discuss how partnership between academia and industry can accelerate drug development.
Advanced Molecular Tools for Proteome Analyses
Masood Kamali-Moghaddam, Uppsala University, speaking at Advances ibn qPCR and dPCR 2014

Market Reports
Immunoassay Auto Trends 2014
HTStec

This report comprehensively documents current practices and preferences in immunoassays and to understand future user requirements, particularly with respect to immunoassay automation.
Label-Free Binding Analysis Trends 2014
HTStec

This market report summarizes the results of HTStec’s 4th global web-based benchmarking survey on label-free (LF) binding analysis carried out in July 2014. The study was initiated by HTStec as part of its regular (every 2 years) tracking of this life science marketplace. The questionnaire was compiled to address the needs and interests of the LF binding analysis vendor community.
Single Cell Omics 2011
Select Biosciences Ltd

The single cell Omics revolution is the potential transformation of cellular heterogeneity from a source of noise to a source of new, as yet hidden discoveries.
Cancer Targeted Therapies and Immunotherapies Market Forecast
Datamonitor plc

The oncology market has witnessed a sizeable shift of focus away from cytotoxic therapies and antihormonal therapies towards the more lucrative targeted therapies and immunotherapies class in the last decade. This class boasts several of the top-selling anticancer brands overall, and has fueled most of the recent rapid growth of the oncology market as a whole.
Monoclonal Antibodies: 2010
Datamonitor plc

Across the branded prescription pharmaceutical market monoclonal antibodies (MAbs) are forecast to be the strongest performing molecule type, delivering a forecast six year compound annual growth rate of 9.5% over 2009-15, outpacing the growth rates of small molecules, therapeutic proteins and vaccines.
Novel Antibodies & Therapeutic Proteins: Technological Challenges & Future Prospects
Select Biosciences Ltd

This innovative & analytical report can be used to assess market trends & appraise the potential of new antibodies & therapeutic proteins. It provides perspective to gain an in-depth understanding of the marketplace, players, products & leading technologies driving the field.
Scientific News
Featured Article
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.

Antibodies Paving the Way to HIV Vaccine
Researchers uncover factors responsible for the formation of broadly neutralizing HIV antibodies in humans.
Vaccine Against Common Cold Achievable
Researchers suggest that a vaccine against rhinoviruses is possible using variant virus vaccines.
Iron Nanoparticles Make Immune Cells Attack Cancer
Researchers accidentally discover that nanoparticles invented for anemia treatment can trigger the immune system’s ability to destroy tumor cells.
Uncovering Cancer’s ‘Invisibility Cloak’
Researchers discover cancer cell mechanism to become invisible to the body's immune system.
Treating Sepsis with Marine Mitochondria
Mitochondrial alternative oxidase from a marine animal combats bacterial sepsis.
Culex Mosquitoes Do Not Transmit Zika
A study of the Culex species mosquito appears to show that the species does not transmit Zika virus.
Bacteria Use Ranking Strategy to Fight Off Viruses
Researchers have explained why microbes store virus confrontation information sequentially, with most recent attacks first.
Molecular Switch Aids Immune Therapy
Researchers identify strategy to maximise effectiveness of immune therapy through molecular switch controlling immune suppression.
Reprogramming Lymph Nodes to Fight MS
Bioengineers work to reprogram lymph node function to fight multiple sclerosis.
Business News
Immunic Acquires 4SC’S Immunology Portfolio
Company has acquired two promising drug development programs with validated targets known to be relevant in various immune and autoimmune diseases.
MD Anderson Cancer Center, Adaptimmune Form Strategic Alliance
Alliance to expedite development of novel adoptive T-cell therapies for multiple types of cancer.
BioArctic, AbbVie Parkinson's Collaboration
BioArctic announces collaboration with AbbVie to develop antibodies for use in treatment of Parkinson's disease.
Teva, Regeneron Announce Fasinumab Collaboration
Teva and Regeneron's global collaboration to develop and commercialize Fasinumab, an investigational NGF antibody for chronic pain.
ASLAN, Selexis SA Collaborate
Collaboration aims to develop a CHO-K1 cell line for expression of ASLAN004.
Caprion Acquires the Immune Monitoring Laboratory from ImmuneHealth
Caprion Biosciences has announced that the company has acquired the assets of the immune monitoring laboratory of ImmuneHealth, ASBL.
BioLineRx, Genentech Collaborate
Collaboration aims to investigate combination of BL-8040 with Atezolizumab in multiple oncology indications.
Fate Therapeutics Partner With MSK
Partnership aims to produce off-the-shelf T-cell product candidates from pluripotent cell lines.
MorphoSys Initiates Phase 2/3 B-MIND trial with MOR208 in DLBCL
The B-MIND trial will evaluate the safety and efficacy of MOR208 combined with the chemotherapeutic agent bendamustine in comparison to rituximab plus bendamustine.
Leap Acquires Macrocure
Leap Therapeutics is to acquire Macrocure following a merger agreement signing.

Events
World Bispecific 2016
28 Sep 2016
World Bispecific 2016 ...
Antibodies & Antibody Drug Con
29 Sep 2016
Antibodies & Antibody Drug Con ...
Microbiome R&D and Business Co
03 Oct 2016
Microbiome R&D and Business Co ...
World Vaccine Congress Europe
10 Oct 2016
World Vaccine Congress Europe ...

ePosters
Development and Application of Quantitative Immunoassays for Major Milk Allergens Bos d 5 (β-lactoglobulin) and Bos d 11 (β-casein)
1. Indoor Biotechnologies, Ltd., Cardiff, Wales, UK. 2. INRA, Gif-sur-Yvette, France

In this study, we sought to develop accurate, sensitive and reliable assays that would enable quantification of multiple milk allergens.
Touching BACE. How Inhibiting β-Amyloid Production by Steric Hindrance with a Novel Immunotherapy Improves Memory in PDAPP Mice
1. School of Pharmacy and Pharmaceutical Sciences, 2. School of Psychology Cardiff University, Cardiff, UK

The work presented in this poster aims to assess whether intracerebroventricular (ICV) administration of 2B3 alleviated age dependent memory deficits in PDAPP mice and to determine whether 2B3 altered APP metabolism and NMDA receptor phosphorylation ex vivo.
Quantitative Cell-Based Bioassays for Individual and Combination Immune Checkpoint Immunotherapy Targets
Promega Corporation

Immune checkpoint receptors are promising new immunotherapy
targets for the treatment of a variety of diseases including cancer and
autoimmune-mediated disorders. We developed a suite of cell-based
bioluminescent reporter bioassays for individual and combination
immune checkpoint immunotherapy targets including: PD-1 (PD-L1 or PD-L2), CTLA-4, LAG-3, TIGIT, PD-1+TIGIT, GITR, 4-1BB, CD40, and OX40.

Mobility of Aeroallergens in Home: Effect of Location of Air Sampling and Implication for Evaluation of Patient Exposure
1Inspirotec Inc, Chicago, IL, Kenilworth Medical Allergy & Immunology, Kenilworth, IL

The Inspirotec sampler permitted the easy testing of multiple locations within a household. Air sampling simultaneously at 12 locations by other technologies would have been technically challenging. These were run by an untrained operator.
A Simple Plate Based Assay Using pH Sensor Dye to Screen for Internalizing Antibody
Promega Corporation

Receptor mediated internalization is a key mechanism of action (MOA) for antibody drug conjugates (ADCs). However, current methods of studying antibody internalization have several limitations including: 1) A multistep process not suitable for screening; 2) Low signal-to-background ratios; 3) Not suitable for kinetic measurements. We have developed a method that mitigates problems associated with traditional internalization assays.
Better Cell-Based Assays for Anti-CTLA-4, Anti-PD-1/PD-L1, and Bispecific Immunotherapy Drug Studies
Promega Corporation

Here we report the development of a panel of robust reporter assays to measure the potencies for biologics in immunotherapy. These assays reflect mode of action and can serve as valuable tools in immunotherapy drug development and discovery.
Development of a Robust Reporter-based T cell Activation Assay for Therapeutic Biologics in Immunotherapy
Promega Corporation

Jurkat T-cells stably expressing luciferase reporter driven by IL2 promoter or NFAT-RE, are used as effector cells. Tumor cell lines endogenously expressing cancer antigen are used as antigen presenting cells (APC). By co-cultivating the two cell lines in the presence of CD3 bispecific antibody, TCR/CD3 is activated in Jurkat effector cells. Luciferase activity is up regulated through IL-2 promoter or NFAT-RE activation.
Reporter Bioassays to Assess Therapeutic Antibodies for Immunotherapy Programs
Promega Corporation

Immunotherapy, also called biologic therapy or biotherapy, stimulates certain parts of the immune system to fight diseases such as cancer. Important drug targets in immunotherapy include: Co-inhibitory receptors, such as PD-1/PD-L1, CTLA-4, LAG3, Tim3; and co-stimulatory receptors, such as GITR, CD40, OX40, 4-1BB.
Current approaches to assaying these targets are cumbersome and variable. Here we offer an improved in vitro bioassay approach.
Modelling CLL cell and T-cell Migration in a Dynamic Circulating Model of CLL
'Cardiff CLL Research Group, Institute of Cancer & Genetics, School of Medicine, Cardiff University, Heath Park, Cardiff, UK. 2CRUK Institute for Cancer Studies, University of Birmingham, Vincent Driv

We have recently developed a novel circulating model of chronic lymphocytic leukaemia (CLL) that mimics the transient interactions that take place between circulating lymphocytes and vascular endothelium. Here we show that both normal and malignant lymphocytes actively underwent transendothelial migration.
Quantification of Natural Killer Cell-Mediated Cytotixicity using Celigo Imaging Cytometry
Nexcelom Bioscience LLC, The University of Texas MD Anderson Cancer Center

Time-course tracking of % lysis eliminates multiple controls & the effect of non-uniform cell seeding in the final cytotoxicity calculation. The # of cells used is less than the cells needed for Release assays & Flow Cytometry. Flow cytometry & Release assays require a seeding density of 100K target cells increasing the number of effector cells to the millions. The visual observation of ADCC or CDC on the images can be convincing to conclude the functionality of antibodies or complements.
Application Notes
Evaluation of the IntelliQube® for Gene Expression Analysis using a One-Step RT-PCR Workflow
Douglas Scientific

A recent study demonstrates the ability of the IntelliQube® and associated Array Tape®, to process RNA samples using a one-step RT-PCR workflow, opening the door to a variety of RNA screening applications including gene expression or viral detection and quantification.
ENRICHMENT AND PURIFICATION OF CD3+ T-CELLS FROM HUMAN UMBILICAL CORD BLOOD
Quad Technologies

Quad Technologies’ has partnered with the University of Massachusetts Medical School (Worcester, MA, USA) to evaluate the performance of the MagCloudz™ Streptavidin cell separation kit.
Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies
Malvern Instruments Limited

The rapid growth of the therapeutic antibody market has increased the interest in modeling of the antibody structure and in understanding the factors that affect the function and the stability of antibodies.
Engineering Monoclonal Antibodies to Enhance Drugability: A Case Study
Malvern Instruments Limited

In this manuscript we compare the stability of three different engineered antibodies as determined by SEC-HPLC analysis during accelerated stability studies, with the stability predicted by DSC.
Characterization of IgG Monomers & Their Aggregates
Malvern Instruments Limited

In this application note we characterize two antibody samples using column calibration and multi-detection SEC.
Understanding Antibody and Viral Glycoprotein Interactions Using CG-MALS
Wyatt Technology Corporation

We used size-exclusion chromatography coupled with multi-angle light scattering to determine the molar mass and native oligo-meric state of a viral glycoprotein.
Charge and Interaction Analysis for Predicting Antibody Formulation Stability
Wyatt Technology Corporation

Colloidal stability is a key solution property of a biotherapeutic formulations, indicative of long-term stability. As it is readily measured over much shorter time scales than long-term stability testing or even accelerated testing regimens, measurements of colloidal stability are often utilized in the course of formulation work to screen out poorly behaved conditions.
Performing ADCC Reporter Bioassay with an Environmentally Controlled Microplate Reader
Tecan Group Ltd.

The Promega ADCC Reporter Bioassay provides effector and target cells in frozen, thaw-and-use format, removing the need for isolating or culturing cells in order to perform the assay. Reporter induction requires a six-hour to overnight incubation in a standard cell culture incubator. The CO2 and temperature control features of the Tecan Infinite® 200 PRO with GCM allow the assay induction to be performed without the requirement for a cell culture incubator.
Tag-lite® two-cell assay: a valuable tool for protein drug discovery
Tecan Group Ltd.

Antibodies are central mediators of the immune system, IgG being the most dominant. Binding of IgG/antigen complexes to membrane-bound Fc? receptors triggers a cellular immune response. Alterations in the Fc portion of the antibody by introducing mutations can lead to complete abolition of Fc? receptor binding. This describes the development of a cellbased TR-FRET assay to determine the simultaneous binding of an antibody to its antigen and huFc?RIIIa present on different cells.
Transcreener® ADP2 TR-FRET Red Assay
Tecan Group Ltd.

Adenosine diphosphate (ADP) is an important mediator of cellular metabolism that is essential for maintaining energy levels. The Transcreener ADP2 TR-FRET Red Assay is intended for the detection of ADP production by any kinase or ATPase, and has been developed specifically for high throughput screening applications.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!